In yesterday’s Wall Street session, Amicus Therapeutics Inc (NASDAQ:FOLD) shares traded at $11.54, down -2.29% from the previous session.
FOLD stock price is now -11.48% away from the 50-day moving average and -6.84% away from the 200-day moving average. The market capitalization of the company currently stands at $3.41B.
With the price target enhanced from $15 to $20, Morgan Stanley Upgraded its rating from Equal-Weight to Overweight for Amicus Therapeutics Inc (NASDAQ: FOLD). On September 09, 2022, Morgan Stanley recently initiated its ‘Equal-Weight’ rating on the stock quoting a target price of $14, while ‘Goldman’ rates the stock as ‘Neutral’
In other news, MCGLYNN MARGARET G, Director sold 7,500 shares of the company’s stock on Mar 05 ’24. The stock was sold for $100,500 at an average price of $13.40. Upon completion of the transaction, the Director now directly owns 59,289 shares in the company, valued at $0.68 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’24, Director MCGLYNN MARGARET G sold 7,500 shares of the business’s stock. A total of $99,675 was realized by selling the stock at an average price of $13.29. This leaves the insider owning 59,289 shares of the company worth $0.68 million. A total of 3.00% of the company’s stock is owned by insiders.
During the past 12 months, Amicus Therapeutics Inc has had a low of $9.70 and a high of $14.57. As of last week, the company has a debt-to-equity ratio of 2.78, a current ratio of 2.88, and a quick ratio of 2.52. The fifty day moving average price for FOLD is $12.98 and a two-hundred day moving average price translates $12.39 for the stock.
The latest earnings results from Amicus Therapeutics Inc (NASDAQ: FOLD) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.11, missing analysts’ expectations of -$0.06 by -0.05. This compares to -$0.19 EPS in the same period last year. The net profit margin was -37.96% and return on equity was -107.04% for FOLD. The company reported revenue of $115.08 million for the quarter, compared to $88.1 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 30.63 percent. For the current quarter, analysts expect FOLD to generate $111.74M in revenue.
Amicus Therapeutics Inc(FOLD) Company Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
